SUPPORTED BY :
MEDIA PARTNER :
ORGANIZED BY
 
 
 
 
Kenya is one of the most stable democracies in Africa. The Government welcomes, promotes and protects private enterprise. In addition, Kenya’s competitive advantage for the health and pharmaceutical sector investment is supported by various investor friendly factors that include:
   
Trademark and patent protection
Access to the regional market
Stable political climate
Investment insurance
Strategic location
 
 
------------------------------------------------------------------------------------------------------------------------------------------------------
 
   
Kenya is currently the largest producer of pharmaceutical products in the Common Market for Eastern and Southern Africa (COMESA) region, supplying about 50% of the regions’ market. Out of the region’s estimated of 50 recognized pharmaceutical manufacturers; approximately 30 are based in Kenya
   
Kenya's pharmaceutical industry is on a rebound, riding on the back of increased expenditure in healthcare and general economic growth over the years
   
The rapid growth of the pharmaceutical market in the region has presented the need to increase quantity of production, and also increase the export ratio for quality products. Kenya is currently the largest producer of pharmaceutical products in the Common Market for Eastern and Southern Africa (COMESA) region, supplying about 50 percent of the region’s market
   
The country’s pharmaceutical and consumer health market is estimated to be worth an estimated USD 160 million each year
 
Sales of over-the-counter (OTC) and prescription drugs clocked up sales of 17.7 billion Kenyan shillings (USD 234.6 million) in 2008, up 22.9% from Sh14.4 billion the previous year, according to the Kenya Pharmaceutical and Health Report 2010
 
 
All rights are reserved to Kenya Pharma Expo